New York City, NY -- (SBWIRE) -- 08/15/2013 -- StockMarketIntel.com issues a special report on the following stocks: Cloud Security Corp (OTCBB:CLDS), Vasomedical, Inc. (OTCBB:VASO), Cellceutix Corp (OTCBB:CTIX), FREDDIE MAC PFD Z (OTCBB:FMCKJ)
Cloud Security Corp (OTCBB:CLDS) gained 3.28%, trading on 512,601 shares, to end the trade at $0.315. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.11 and was moved to the maximum level of $1.47. The stock changed hands in a range of $0.30 to $0.32, bringing its market capitalization to about $30.70 million. Cloud Security Corp., a development stage company, operates as an information technology services and software company. It primarily delivers access to computer desktops and other consumer electron devices from remote locations.
For How Long CLDS Gloss will Attract Investors? Find out via this report
Vasomedical, Inc. (OTCBB:VASO) declined -11.07%, to complete the trading session at $0.240, with a total volume of 26,287 shares. The stock, on average, trades on a volume of 377,004 shares. In the past 52 weeks, the share price has not declined below $0.10 and above $0.37. It floated in a range of $0.18 to $0.18 during the last trading session, with a beta value of 1.49. Its market capitalization now moved to about $37.37 million. Vasomedical, Inc., together with its subsidiaries, engages in designing, manufacturing, marketing, and supporting enhanced external counterpulsation (EECP) systems, ambulatory monitoring devices, and patient management devices.
Is it the Right to Grab VASO after the Recent Slump? Get Free Trend Analysis Here
Cellceutix Corp (OTCBB:CTIX) was in a range of $1.96-$2.00 before closing at $1.96. The share price hit its 52-week low of $0.60 and $2.47 was the best price. The stock completed the day with a total volume of 81,765 shares, versus an average volume of 309,198 shares. Cellceutix Corporation, a development stage biopharmaceutical company, engages in the discovery and development of small molecule drugs to treat diseases primarily in the areas of cancer and inflammatory disease. Its product candidates include Kevetrin, which is in Phase 1 trial for various solid tumor cancer types in patients with advanced-stage cancers.
Is CTIX a Solid Investment at These Levels? Read This Report For Details
FREDDIE MAC PFD Z (OTCBB:FMCKJ) declined -0.85% yesterday, bringing its market capitalization around $1.13 billion. The total number of shares that changed hands during the session was 913,456 shares, as compared to average trading volume of 1.42 million shares. The share price, after opening at $4.70, made a high of $4.70 and hovered above $4.60 to end the day at $4.69.
Will FMCKJ Reach the Bottom after Yesterday’s Correction? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)